LL-37 vs Oxytocin
Updated July 27, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of LL-37 and Oxytocin (also searched as Oxytocin vs LL-37) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
LL-37 centers on healing, while Oxytocin leans toward neuro. On indexed research, Oxytocin is ahead (LL-37: 7 studies, Human evidence; Oxytocin: 8, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •LL-37 is strongest for healing; Oxytocin for neuro.
- •Evidence: LL-37 Human evidence (7 studies) vs Oxytocin Human evidence (8).
- •Check the FDA-approval status chips above before assuming a legal use pathway.
Effect profiles, overlaid
At a glance
LL-37 vs Oxytocin: side-by-side
| Metric | LL-37 | Oxytocin |
|---|---|---|
| Class | Immune | Hormonal |
| Regulatory status | Research use only | FDA-approved |
| Evidence grade | Human evidence | Human evidence |
| Studies indexed | 7 | 8 |
| Research level | Well Studied | FDA Approved |
| Strongest effect | Healing & recovery | Neuro & mood |
| Healing & recovery | 4.0▲ | 2.0 |
| Muscle & body comp | 0.0 | 0.0 |
| Metabolic & appetite | 0.0 | 0.0 |
| Neuro & mood | 0.0 | 4.0▲ |
| Sleep & circadian | 0.0 | 1.0▲ |
| Inflammation & immune | 4.0▲ | 1.0 |
| Skin & aesthetics | 0.0 | 0.0 |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | LL-37 | Oxytocin |
|---|---|---|
| Mechanism | Disrupts microbial membranes; modulates immune responses | Oxytocin receptor agonist |
| Route | — | Intravenous injection; Subcutaneous injection; Intranasal administration |
| Half-life | — | ~3-5 min |
| Time to peak | — | ~30 min |
| Duration of action | — | 1-2 hours |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is LL-37?
### LL-37 Summary LL-37 is a human cathelicidin antimicrobial peptide that plays a crucial role in the innate immune response, exhibiting antimicrobial, immunomodulatory, and wound healing properties. Its diverse functions make it a subject of interest in various fields of biomedical research.
Full LL-37 profile, mechanism & studies →What is Oxytocin?
### Oxytocin Summary Oxytocin is a neuropeptide that plays a crucial role in social bonding, reproductive behaviors, and emotional regulation. Its functions extend to various physiological processes, including childbirth and lactation, and it has garnered interest for its potential therapeutic applications in mental health and social disorders.
Full Oxytocin profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | LL-37 | 4.0/5 effect signal |
| Neuro | Oxytocin | 4.0/5 effect signal |
| Sleep | Oxytocin | 1.0/5 effect signal |
| Inflammation | LL-37 | 4.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack LL-37 and Oxytocin?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
LL-37 vs Oxytocin: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
LL-37 has 7 approved studies indexed (Human evidence), and Oxytocin has 8 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is LL-37 or Oxytocin better?
It depends on your goal. LL-37 is strongest for healing; Oxytocin for neuro. Oxytocin has more indexed studies (8). See the goal-by-goal breakdown above.
Which has more research, LL-37 or Oxytocin?
LL-37 has 7 approved studies indexed (Human evidence); Oxytocin has 8 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack LL-37 and Oxytocin?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of LL-37 vs Oxytocin?
LL-37: no community-reported effects logged yet. Oxytocin: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is LL-37 or Oxytocin FDA-approved?
LL-37 is a research-use compound and is not FDA-approved. Oxytocin is FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is Oxytocin better than LL-37?
For neuro, Oxytocin has the edge; for healing, LL-37 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 27, 2026.